PAZOPANIB HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H23N7O2S.ClH
Molecular Weight	473.979
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CN(C1=CC2=NN(C)C(C)=C2C=C1)C3=CC=NC(NC4=CC=C(C)C(=C4)S(N)(=O)=O)=N3

InChI

InChIKey=MQHIQUBXFFAOMK-UHFFFAOYSA-N

InChI=1S/C21H23N7O2S.ClH/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16;/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25);1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C21H23N7O2S
Molecular Weight	437.518
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022465s-010S-012lbl.pdf
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800016874 | https://www.ncbi.nlm.nih.gov/pubmed/26767042 | https://www.ncbi.nlm.nih.gov/pubmed/17620431

Pazopanib (VOTRIENT) is an orally bioavailable multi-targeted tyrosine kinase receptor inhibitor. Pazopanib inhibits vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR) -1 and -3, cytokine receptor (Kit), interleukin-2 receptor inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). In an vitro study, pazopanib exerted anti-tumor effect through mechanisms including the Raf-MAPK/ERK (MEK)-extracellular signal-regulated kinase (ERK) pathway. It has good oral exposure and inhibits angiogenesis and tumor growth in mice. Pazopanib (VOTRIENT) was developed by GlaxoSmithKline for the treatment of solid tumours and age-related macular degeneration. However, Novartis acquired all the rights to the drug from GlaxoSmithKline. Pazopanib (VOTRIENT) is indicated for the treatment of patients with advanced renal cell carcinoma and advanced soft tissue sarcoma.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Fibroblast growth factor receptor 1 44 Target ID: CHEMBL3650 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17620431/	Inhibitor 8146	0.14 µM [IC50]
Fibroblast growth factor receptor 3 31 Target ID: CHEMBL2742 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17620431/	Inhibitor 8146	0.13 µM [IC50]
Macrophage colony stimulating factor receptor 22 Target ID: CHEMBL1844 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17620431/	Inhibitor 8146	0.146 µM [IC50]
Platelet-derived growth factor receptor alpha 29 Target ID: CHEMBL2007 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17620431/	Inhibitor 8146	0.071 µM [IC50]
Platelet-derived growth factor receptor beta 54 Target ID: CHEMBL1913 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17620431/	Inhibitor 8146	0.084 µM [IC50]
Stem cell growth factor receptor 51 Target ID: CHEMBL1936 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17620431/	Inhibitor 8146	0.074 µM [IC50]
Tyrosine-protein kinase ITK/TSK 3 Target ID: CHEMBL2959 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17620431/	Inhibitor 8146	0.43 µM [IC50]
Tyrosine-protein kinase LCK 10 Target ID: CHEMBL258 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17620431/	Inhibitor 8146	0.411 µM [IC50]
Vascular endothelial growth factor receptor 1 39 Target ID: CHEMBL1868 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17620431/	Inhibitor 8146	0.01 µM [IC50]
Vascular endothelial growth factor receptor 2 100 Target ID: CHEMBL279 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17620431/	Inhibitor 8146	0.03 µM [IC50]
Vascular endothelial growth factor receptor 3 39 Target ID: CHEMBL1955 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17620431/	Inhibitor 8146	0.047 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Renal cell carcinoma 27 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022465s-010S-012lbl.pdf https://www.ncbi.nlm.nih.gov/pubmed/22341567	Primary		Approved 8307	VOTRIENT Approved Use VOTRIENT® is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). VOTRIENT is indicated for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. Limitation of Use: The efficacy of VOTRIENT for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors has not been demonstrated. VOTRIENT is a kinase inhibitor indicated for the treatment of patients with: •advanced renal cell carcinoma. (1) •advanced soft tissue sarcoma who have received prior chemotherapy. (1) Limitation of Use: The efficacy of VOTRIENT for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. Launch Date 1.25591041E12
Soft tissue sarcoma 9 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022465s-010S-012lbl.pdf https://www.ncbi.nlm.nih.gov/pubmed/23488774	Primary		Approved 8307	VOTRIENT Approved Use VOTRIENT® is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). VOTRIENT is indicated for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. Limitation of Use: The efficacy of VOTRIENT for the treatment of patients with adipocytic STS or gastrointestinal stromal tumors has not been demonstrated. VOTRIENT is a kinase inhibitor indicated for the treatment of patients with: •advanced renal cell carcinoma. (1) •advanced soft tissue sarcoma who have received prior chemotherapy. (1) Limitation of Use: The efficacy of VOTRIENT for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. Launch Date 1.25591041E12

C_max

Value	Dose	Analyte	Population
44.8 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31125423	800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered:	PAZOPANIB blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
50.2 mg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31125423	600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	PAZOPANIB blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
58.1 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	PAZOPANIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
821 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31125423	800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered:	PAZOPANIB blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
895 mg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31125423	600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	PAZOPANIB blood	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
1037 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf	800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered:	PAZOPANIB plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022465s-010S-012lbl.pdf			PAZOPANIB plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: PAZOPANIB Page: p. 61	unhealthy, 59 years n = 290 Health Status: unhealthy Condition: renal cell carcinoma Age Group: 59 years Sex: M+F Population Size: 290 Sources: PAZOPANIB Page: p. 61	Disc. AE: Proteinuria... AEs leading to discontinuation/dose reduction: Proteinuria (5 patients) Sources: PAZOPANIB Page: p. 61
800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_MedR.pdf Page: p. 61	unhealthy, 59 years n = 290 Health Status: unhealthy Condition: renal cell carcinoma Age Group: 59 years Sex: M+F Population Size: 290 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_MedR.pdf Page: p. 61	Disc. AE: ALT increased, AST increased... AEs leading to discontinuation/dose reduction: ALT increased (11 patient) AST increased (11 patient) Bilirubin increased (11 patient) Myocardial infarction (6 patients) Ischemic stroke (6 patients) Transient ischemic attack (6 patients) Fatigue (5 patients) Diarrhea (7 patients) Anorexia (7 patients) Vomiting (7 patients) Proteinuria (3 patients) Hypertension (2 patients) Hemorrhage (2 patients) Confusion (12 patients) Infection (12 patients) Hand-and-foot syndrome (12 patients) Edema (12 patients) Dehydration (12 patients) Anemia (12 patients) Anxiety (12 patients) Convulsion (12 patients) Atrial fibrillation (12 patients) Hypertension (20 patients) Gastrointestinal disturbance (17 patients) Liver function test abnormal (16 patients) Fatigue (10 patients) Hematologic disorder (4 patients) Rash (5 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_MedR.pdf Page: p. 61
600 mg 1 times / day multiple, oral MTD Dose: 600 mg, 1 times / day Route: oral Route: multiple Dose: 600 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21831954	unhealthy, 61 years (range: 38–76 years) n = 8 Health Status: unhealthy Condition: Hepatocellular Carcinoma Age Group: 61 years (range: 38–76 years) Sex: M+F Population Size: 8 Sources: https://pubmed.ncbi.nlm.nih.gov/21831954	DLT: Neutropenia, Aspartate aminotransferase increased... Other AEs: Diarrhea, Hypertension... Dose limiting toxicities: Neutropenia (grade 2, 1 patient) Aspartate aminotransferase increased (grade 2, 1 patient) Hyperbilirubinemia (grade 2, 1 patient) Other AEs: Diarrhea (all grades, 50%) Hypertension (grade 3, 13%) AST increased (grade 3, 13%) ALT increased (all grades, 25%) Cough (all grades, 13%) Skin hypopigmentation (all grades, 50%) Weight decrease (all grades, 25%) Alopecia (all grades, 13%) Dizziness (all grades, 13%) Hyperbilirubinemia (all grades, 25%) Abdominal distension (all grades, 25%) Abdominal pain (all grades, 25%) Fatigue (all grades, 13%) Leukopenia (all grades, 13%) Muscle spasms (all grades, 25%) Upper respiratory tract infection (all grades, 13%) Hypercholesterolemia (grade 3, 13%) Gastrointestinal hemorrhage (grade 4, 13%) Hypoglycemia (grade 4, 13%) Transaminases increased (grade 4, 13%) Sources: https://pubmed.ncbi.nlm.nih.gov/21831954
800 mg 1 times / day multiple, oral Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21831954	unhealthy, 61 years (range: 38–76 years) n = 5 Health Status: unhealthy Condition: Hepatocellular Carcinoma Age Group: 61 years (range: 38–76 years) Sex: M+F Population Size: 5 Sources: https://pubmed.ncbi.nlm.nih.gov/21831954	DLT: Aspartate aminotransferase increase, Malaise... Dose limiting toxicities: Aspartate aminotransferase increase (grade 3, 2 patients) Malaise (grade 3, 2 patients) ALT increased (grade 3, 2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/21831954
800 mg 1 times / day multiple, oral Recommended Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: advanced renal cell carcinoma Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf	Other AEs: Hepatotoxicity... Other AEs: Hepatotoxicity (severe\|grade 5) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf
2000 mg 1 times / day multiple, oral Highest studied dose Dose: 2000 mg, 1 times / day Route: oral Route: multiple Dose: 2000 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_MedR.pdf	unhealthy n = 3 Health Status: unhealthy Population Size: 3 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_MedR.pdf	DLT: Fatigue... Dose limiting toxicities: Fatigue (grade 3, 1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_MedR.pdf
1000 mg 1 times / day multiple, oral Dose: 1000 mg, 1 times / day Route: oral Route: multiple Dose: 1000 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_MedR.pdf	unhealthy n = 3 Health Status: unhealthy Population Size: 3 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_MedR.pdf	DLT: Hypertension... Dose limiting toxicities: Hypertension (grade 3, 1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022465lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_MedR.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1670 inhibitor 1532 inducer 753	inhibitor 1695	inhibitor 1789	inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1463 CYP2B6 770 CYP2C8 869 CYP2C19 1410 CYP2E1 846 P-gp 1401 UGT1A1 200 OATP1B1 770	CYP1A2 1013 CYP2C8 670 P-gp 1491	CYP2B6 521 CYP1A2 671

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP2C8 923	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32.0	moderate [IC50 10 uM]	weak (co-administration study) Comment: AUC of paclitaxel (CYP3A4 and CYP2C8 substrate) increased by 26%, decreased paclitaxel clearance by 14%, and increased paclitaxel Cmax by 31%; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32.0
CYP2C19 1484	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32,36	moderate [IC50 11 uM]	no (co-administration study) Comment: no effect Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32,36
CYP3A4 1857	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=33 Page: 33,37	moderate [IC50 11 uM]	weak (co-administration study) Comment: pazopanib increased the AUC of CYP3A4 substrate (midazolam) by 32%; AUC of paclitaxel (CYP3A4 and CYP2C8 substrate) increased by 26%, decreased paclitaxel clearance by 14%, and increased paclitaxel Cmax by 31%; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=33 Page: 33,37
CYP2B6 946	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32.0	moderate [IC50 15 uM]
CYP1A2 1620	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32,36	moderate [IC50 16 uM]	no (co-administration study) Comment: no effect Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32,36
CYP2E1 929	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32.0	moderate [IC50 17 uM]
CYP2D6 1826	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32,37	moderate [IC50 18 uM]	yes (co-administration study) Comment: increased the AUC of CYP2D6 substrate (dextromethorphan) by 64% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32,37
CYP2C9 1747	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32,36	moderate [IC50 7.9 uM]	no (co-administration study) Comment: no effect Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32,36
CYP2B6 946	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32,33	moderate
CYP3A4 1857	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32,33,37	moderate	weak (co-administration study) Comment: pazopanib increased the AUC of CYP3A4 substrate (midazolam) by 32%; AUC of paclitaxel (CYP3A4 and CYP2C8 substrate) increased by 26%, decreased paclitaxel clearance by 14%, and increased paclitaxel Cmax by 31%; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32,33,37
CYP1A2 1620	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=33 Page: 33.0	no
P-gp 1588	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=34 Page: 34.0	no
OATP1B1 785	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=34 Page: 34.0	yes [IC50 0.79 uM]
UGT1A1 249	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=34 Page: 34,4	yes [IC50 1.2 uM]	yes (pharmacogenomic study) Comment: Certain UGT1A1 genotypes are associated with an increase in the risk of pazopanib induced hyperbilirubinemia. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=34 Page: 34,4

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP3A4 1670	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32,35	major	yes (co-administration study) Comment: pazopanib AUC (0-t), Cmax, and half-life were increased 1.47, 2.21, and 2.81 fold, respectively; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32,35
CYP1A2 1013	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32.0	minor
CYP2C8 670	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=32 Page: 32.0	minor
P-gp 1491	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=34 Page: 34,35	yes	yes (co-administration study) Comment: AUC(0-t) and Cmax values of pazopanib are increased by 59 and 50%, respectively, when coadministered with lapatinib; Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf#page=34 Page: 34,35

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_PharmR.pdf#PAGE=68 Page: 68.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:71219	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:71219
MolPort	MolPort-006-827-156	https://www.molport.com/shop/molecule-link/MolPort-006-827-156
Selleck Chemicals	pazopanib	http://www.selleckchem.com/products/pazopanib.html
ZINC	ZINC000011617039	http://zinc15.docking.org/substances/ZINC000011617039
eMolecules	30151586	https://www.emolecules.com/cgi-bin/more?vid=30151586

PubMed

Title	Date	PubMed
Recent advances in the therapy of renal cancer.	2007 Feb	17250461
Neovascular age-related macular degeneration: potential therapies.	2008	18484796
Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.	2008 Dec	19075590
HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?	2008 Jun	18537532
[Systemic therapy of metastasizing renal cell carcinoma].	2008 Oct	18825295
Signaling inhibitors in metastatic renal cell carcinoma.	2008 Sep-Oct	18836338
Targeted therapy in the treatment of metastatic renal cell cancer.	2009	20130440
Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.	2009	19744307
Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer.	2009	19664181
Emerging pharmacologic therapies for wet age-related macular degeneration.	2009	19622904
Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib.	2009 Apr	19365030
Systemic therapy of advanced urothelial cancer.	2009 Aug	19408129
Metastatic renal cell carcinoma: recent advances in the targeted therapy era.	2009 Dec	19748725
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).	2009 Jul 1	19451427
Phase I trial of pazopanib in patients with advanced cancer.	2009 Jun 15	19509175
[Chemotherapy for breast cancer refractory to anthracycline, taxane or trastuzumab].	2009 May	19461171
VEGF inhibitors for the treatment of neovascular age-related macular degeneration.	2009 May	19388880
Targeted therapies in metastatic renal cancer in 2009.	2009 May	19338565
VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation.	2009 Sep 18	19763275
Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.	2009 Sep 8	19427156
Targeted therapies in epithelial ovarian cancer.	2010	20111741
A current review of targeted therapeutics for ovarian cancer.	2010	20069122
Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma.	2010 Aug	20163917
Anti-angiogenesis agents in metastatic or recurrent cervical cancer.	2010 Feb	19861227
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.	2010 Feb 20	20100962
StatBite: FDA oncology drug product approvals in 2009.	2010 Feb 24	20145211
Pazopanib.	2010 Jan	20043026
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.	2010 Jan	20006922
An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer.	2010 Jul	20032126
[Antiangionic drugs in soft tissue sarcoma].	2010 Jun	20483703
Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma.	2010 Jun	20407031
Recent advances and future directions in the management of metastatic renal cell carcinoma.	2010 Mar	20184547
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?	2010 Mar	20012482
Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.	2010 May	20469994
Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma.	2010 May	20113155

Patents

Sample Use Guides

In Vivo Use Guide

800 mg orally once daily without food (at least 1 hour before or 2 hours after a meal). Baseline moderate hepatic impairment – 200 mg orally once daily. Not recommended in patients with severe hepatic impairment.

Route of Administration: Oral

In Vitro Use Guide

Treatment of the KATO-III, OCUM-2M, SNU-16, and HSC-39 gastric cancer cell lines harboring FGFR2 amplification with pazopanib resulted in marked decreases of cell survival with IC50 in ranges of 0.1 to 2.0 uM, whereas the same treatment of those cell lines without FGFR2 amplification had no growth-inhibitory effects

Substance Class	Chemical Created by `admin` on `Fri Dec 16 20:22:51 UTC 2022` Edited by `admin` on `Fri Dec 16 20:22:51 UTC 2022`
Record UNII	33Y9ANM545
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PAZOPANIB HYDROCHLORIDE

Official Name

English

PAZOPANIB HCL

Common Name

English

GW786034B

Code

English

Pazopanib hydrochloride [WHO-DD]

Common Name

English

PAZOPANIB HYDROCHLORIDE [MART.]

Common Name

English

BENZENESULFONAMIDE, 5-((4-((2,3-DIMETHYL-2H-INDAZOL-6-YL)METHYLAMINO)-2-PYRIMIDINYL)AMINO)-2-METHYL-, MONOHYDROCHLORIDE

Common Name

English

VOTRIENT

Brand Name

English

PAZOPANIB HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

GW-786034B

Code

English

PAZOPANIB (AS HYDROCHLORIDE)

Common Name

English

PAZOPANIB MONOHYDROCHLORIDE

Common Name

English

PAZOPANIB HYDROCHLORIDE [USAN]

Common Name

English

PAZOPANIB HYDROCHLORIDE [MI]

Common Name

English

PAZOPANIB HYDROCHLORIDE [JAN]

Common Name

English

5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide monohydrochloride

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1742